李慧

　　研究员，二级PI，博士生导师，主要从事肿瘤免疫微环境的研究以及基于蛋白敲除技术的肿瘤靶向治疗的新技术开发。现任中国医药生物技术协会医药生物技术临床应用专业委员会委员兼学术秘书、中国免疫学会会员。

　　受教育经历

　　2002/09-2005/07天津医科大学肿瘤学专业，博士

　　1999/09 -2002/07天津医科大学免疫学专业，硕士

　　1992/09 -1996/07南开大学生物化学专业，学士

　　研究工作经历

　　2012/11-至今天津医科大学附属肿瘤医院，研究员

　　2007/11-2012/11天津医科大学附属肿瘤医院，副研究员

　　2002/11-2007/11天津医科大学附属肿瘤医院，助理研究员

　　1996/07-2002/11天津医科大学附属肿瘤医院，研究实习员

　　近3年发表学术论文

　　1) F Kong, J Zhang, Y Li, X Hao, X Ren, H Li*, P Zhou*. Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases. Oncogene (In Press)

　　2) Yu X, Li H*, Ren X*. Interaction between regulatory T cells and cancer stem cells. Int J Cancer. 131(7): 1491-1498, 2012.

　　3) Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H*. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 61(11): 2125-2133, 2012.

　　4) Yu X, Li H*, Ren X*. Signaling cascades initiated by TSLP-mediated signals in different cell types. Cell Immunol. 279(2): 174-179, 2012

　　5) Li H, Zhao H, Yu J, Su Y, Cao S, An X, Ren X*. Increased prevalence of regulatory T

　　cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 60(11): 1587-1596, 2011.

　　6) Zhang R, Li H, Yu J, Zhao J, Wang X, Wang G, Yao Z, Wei F, Xue Q, Ren X*. Immunoactivative role of indoleamine 2, 3-dioxygenase in gastric cancer cells in vitro. Mol Med Report. 4(1):169-173, 2011. (Co-first author)

　　7) Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 11(8):1076-83, 2009.

　　8) Li H, Jiang HJ, Ma MQ, Wei F, An XM, Ren XB. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine. Cancer Biother Radiopharm. 22(6):790-8, 2007.

　　9) Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, Huang ZT, Ren XB. CD4 +CD25 +regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 27(3):317-26, 2007.

　　10) Wang Y, Zhang X, Li H, Yu J, Ren X*. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013 Jan 25. [Epub ahead of print]

　　11) Kong F, Li H, Fan Y, Zhang X, Cao S, Yu J, Ren X, Hao X*. Overweight Patients Achieve Ideal Body Weight Following Curative Gastrectomy Resulting in Better Long-Term Prognosis. Obes Surg. 2013 Feb 1. [Epub ahead of print]

　　12) Yue W, Yang BH, Li H, Cao S, Ren XB*, Yu JP*. IDO+ DCs and Signalling Pathways. Curr Cancer Drug Targets. 2013 Jan 14. [Epub ahead of print]

　　13) Zheng YW, Li H, Yu JP, Zhao H, Wang SE, Ren XB*. Interferon-λs: Special Immunomodulatory Agents and Potential Therapeutic Targets. J Innate Immun. 2012 Nov 30. [Epub ahead of print]

　　14) Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X*. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 62(1): 65-73, 2013.

　　15) Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X*. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18(6):1751-1759, 2012.

　　16) Liu R, Li H, Liu L, Yu J, Ren X*. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 13(3):123-129, 2012.

　　17) Qi Y, Li RM, Kong FM, Li H, Yu JP, Ren XB*. How do tumor stem cells actively escape from host immunosurveillance? Biochem Biophys Res Commun. 420(4): 699-703, 2012.

　　18) Zhang J, Yu J, Yang L, Li H, Wei F, Zhao H, Yu W, Ren X*. Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously. Cancer Immunol Immunother. 61(10):1653-1661, 2012.

　　19) Zhang J, Li H, Yu JP, Wang SE, Ren XB*. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 130(9):1971-1980, 2011.

　　20) Yu J, Sun J, Wang SE, Li H, Cao S, Cong Y, Liu J, Ren X*. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. 2011:469135, 2011.

　　21) Sun J, Yu J, Li H, Yang L, Wei F, Yu W, Liu J, Ren X*. Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Clin Cancer Res. 30:82, 2011.

　　22) Yu J, Ren X, Yan F, Li H, Cao S, Chen Y, Sun H, An X, Zhang N, Hao X*. Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells. Transpl Int. 24(2):201-212, 2011.

　　23) Yu J, Ren X, Li H, Cao S, Han Y, Enoki T, Kato I, Cao C, Hao X. Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors. Cancer Biother Radiopharm. 26(4):485-94, 2011.

　　24) Han Y, Yu J, Cao S, Li H, Ren B, An X, Zhang N, Qi J, Ren X*. Fetal-maternal microchimerism enhances the survival effect of interleukin-2-activated haploidentical peripheral blood stem cell treatment in patients with advanced solid cancer. Cancer Biother Radiopharm 25(6):741-746, 2010.

　　获得奖励

　　1)李慧，任宝柱，苏延军，于津浦，曹水，安秀梅，任秀宝，郝希山，DC诱导的CIK细胞治疗非小细胞肺癌的临床与基础研究，天津市人民政府，天津市科技进步二等奖，2009年。

　　2)任秀宝、李慧、于津浦、曹水、尤健、潘源、黄宗堂，安秀梅，恶性实体肿瘤特异性和非特异性免疫细胞治疗基础与临床研究，天津市人民政府，天津市科技进步二等奖，2007年。